Invention Grant
- Patent Title: Osteoclast inhibitors for knee conditions
-
Application No.: US15624428Application Date: 2017-06-15
-
Publication No.: US09861648B2Publication Date: 2018-01-09
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BOIVENTURES II LLC
- Current Assignee: ANTECIP BOIVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Mascoff Brennan Laycock Gilmore
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/675 ; A61K9/00
Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain.
Public/Granted literature
- US20170281655A1 OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS Public/Granted day:2017-10-05
Information query
